Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3065% below fair value
$0.41−0.07 (-14.34%)
Close on Nov 18, 2026Market cap $63.33MP/E –Yield –
Coherus Oncology pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Coherus Oncology's pe ratio was 1.2× on Jul 31, 2026, against 0.5× a year earlier. Over the last 3 years it ranged from 0.3× to 15.7×, with a median of 4.1×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 1.2× | +0.8 |
| 2025 | Dec 31, 2025 | 0.3× | −8.8 |
| 2021 | Apr 30, 2021 | 9.1× | +0.6 |
| 2020 | Dec 31, 2020 | 8.5× | – |
See a number that looks wrong?